Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the 17th Annual BIO CEO & Investor Conference and Leerink Global Healthcare Conference in New York

NEW YORK, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
February 06, 2015 08:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock

NEW YORK, Feb. 6, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced the pricing of its previously announced underwritten...
February 05, 2015 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock

NEW YORK, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that it intends to offer its common stock in an...
January 08, 2015 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Appoints Jason Slakter, MD, Chief Medical Officer, to Board of Directors

NEW YORK, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Jason Slakter, MD, Chief Medical Officer, has...
December 22, 2014 16:01 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Reports Fiscal Year 2014 Financial and Business Results

NEW YORK, Dec. 22, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its fiscal year ended September 30,...
December 19, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Announce Fiscal 2014 Financial Results and Host Conference Call on Monday, December 22

NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a research and development company with a primary focus in ophthalmology, today announced that it will report its...
December 02, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference

NEW YORK, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
October 27, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City

NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst...
October 20, 2014 07:15 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting

Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes Regression of the SHRM Biomarker in Wet-AMD and Vision Improvement is Consistent...
October 14, 2014 07:15 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD

Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months Phase III Trials to Commence in the First Half of 2015 NEW YORK, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ohr...